This study, however, indicates that in the murine model of prostate cancer tumors, at relatively lower activity levels, 177Lu-PSMA-NARI-56 demonstrates superior therapeutic efficacy and higher survival rates compared to 177Lu-PSMA-617. The gene discussed is FOLH1; the disease is Familial prostate cancer.